  Alpha-DaRT is a new method for treating solid tumors with alpha particles,
relying on the release of the alpha-emitting daughter atoms of radium-224 from
sources inserted into the tumor. The most important model parameters for
Alpha-DaRT dosimetry are the diffusion lengths of radon-220 and lead-212, and
their estimation is essential for treatment planning. The aim of this work is
to provide first experimental estimates for the diffusion length of radon-220.
The diffusion length of radon-220 was estimated from autoradiography
measurements of histological sections taken from 24 mice-borne subcutaneous
tumors of five different types. Experiments were done in two sets: fourteen
in-vivo tumors, where during the treatment the tumors were still carried by the
mice with active blood supply, and ten ex-vivo tumors, where the tumors were
excised before source insertion and kept in a medium at 37 degrees C with the
source inside. The measured diffusion lengths of radon-220 lie in the range
0.25-0.6 mm, with no significant difference between the average values measured
in in-vivo and ex-vivo tumors: 0.40 $\pm$ 0.08 mm for in-vivo vs. 0.39 $\pm$
0.07 mm for ex-vivo. However, in-vivo tumors display an enhanced spread of
activity 2-3 mm away from the source. This effect is not explained by the
current model and is much less pronounced in ex-vivo tumors. The average
measured radon-220 diffusion lengths in both in-vivo and ex-vivo tumors lie
close to the upper limit of the previously estimated range of 0.2-0.4 mm. The
observation that close to the source there is no apparent difference between
in-vivo and ex-vivo tumors, and the good agreement with the theoretical model
in this region suggest that the spread of radon-220 is predominantly diffusive
in this region. The departure from the model prediction in in-vivo tumors at
large radial distances may hint at potential vascular contribution.
